Skip to Content


Mitchell Stein, featuring blog post and NEJM article co-authored by Rachel E. Sachs (Academic Fellow Alumna)
ICER
March 31, 2017

Read the full review here
Read Rachel Sachs' blog post
Read Rachel Sachs' NEJM article

From the review:

Democrats’ New Drug Bill

Improving Access to Affordable Prescription Drugs Act was introduced this week. You can read the summary of the bill here. Rachel Sachs takes a deep dive into the significance of the different provisions here. [...]

Looking forward, part of his focus will be on approving “complex generics” faster (loosely defined as involving a drug and delivery device). And finally, Amitabh Chandra, Ph.D., and Rachel E. Sachs, J.D., M.P.H. look at the challenges he will face: An FDA Commissioner for the 21st Century

Read more of the review here! Check out Rachel Sachs' Bill of Health blog post here and her NEJM article here!

Read the full review here
Read Rachel Sachs' blog post
Read Rachel Sachs' NEJM article

Tags

biotechnology   fda   health care finance   health law policy   pharmaceuticals   rachel sachs   regulation